EVALUATION OF ANTI DIABETIC DRUG ALOGLIPTIN FOR THE TREATMENT OF OBESITY IN RATS

  • Mohd. Fasih Ahmad Sunrise University, Bagad Rajput, Alwar – 301030, Rajasthan, India
  • D. J. Mani Babu Hindu College of Pharmacy, Guntur, AP-522002, India
  • Anup Pradhan Sunrise University, Bagad Rajput, Alwar – 301030, Rajasthan, India

Abstract

Obesity is a complex disease caused by the interaction of a myriad of genetic, dietary, lifestyle, and environmental factors, which favors a chronic positive energy balance, and leads to increased body fat mass. The incidence of obesity is rising at an alarming rate and is becoming a major public health concern with incalculable social costs. Indeed, obesity facilitates the development of metabolic disorders such as diabetes, hypertension, and cardiovascular diseases in addition to chronic diseases such as stroke, osteoarthritis, sleep apnea, some cancers, and inflammation based pathologies. Standard reference Sibutramine produced a significant anti obesity activity in HFD induced obesity in rats. Alogliptin with medium and high doses exhibited a significant anti obesity activity by reducing the body weight, food intake, organ and fat pads weight and serum GLU, CHO, TRG, LDL and VLDL cholesterol levels with an increased HDL levels in HFD induced obesity models in rats.


Keywords: Alogliptin, Anti-obesity, Anti-diabetics, DPP-4

Keywords: Alogliptin, Anti-obesity, Anti-diabetics, DPP-4

Downloads

Download data is not yet available.

Author Biographies

Mohd. Fasih Ahmad, Sunrise University, Bagad Rajput, Alwar – 301030, Rajasthan, India

Sunrise University, Bagad Rajput, Alwar – 301030, Rajasthan, India

D. J. Mani Babu, Hindu College of Pharmacy, Guntur, AP-522002, India

Hindu College of Pharmacy, Guntur, AP-522002, India

Anup Pradhan, Sunrise University, Bagad Rajput, Alwar – 301030, Rajasthan, India

Sunrise University, Bagad Rajput, Alwar – 301030, Rajasthan, India

References

1. Dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011; 124:2338–2349.
2. Ervinna N, Mita T, Yasunari E, Azuma K. Alogliptin, DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient rats, Endocrinology, 2013; 154:1260–1270.
3. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y; DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient rats..2011; 58:157–166.
4. Seino Y, Yabe D, Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother; 2014; 15:851–863.
5. Jarvis CI, Cabrera A, Charron D. r.;Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacothe; 2013; 47:1532–1539.
6. Andukuri R, Drincic A, Rendell M;Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes: 2009; 2:117–126.
7. Eur J Pharmacol: Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob rats.. 2008; 588:325–332.
8. Hopsu-Havu VK, Glenner GG;A new dipeptide naphth-ylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie; 1966; 7:197-201.
9. Lambeir AM, Durinx C, Scharpe S, De Meester I; Dipep¬tidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV; Crit Rev Clin Lab Sci 2003;40:209- 294.
10. Rohrborn D, Wronkowitz N, Eckel J; Front Immunol; DPP4 in diabetes. 2015; 6:386.
11. Mulvihill EE, Drucker DJ;Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibi¬tors. Endocr Rev; 2014; 35:992-1019.
12. Xavier F, Obesity: epidemiology and clinical aspects, Clini Gastroenterol, 2004; 18(6):1125–1146.
13. Mayer, J.: Genetic, traumatic and environmental factors in the etiology of obesity. Physiol. Rev., 1953; 33:472–508.
14. Heron, W. T., and Skinner, B. F.: An apparatus for the study of animal behavior. Psychol. Rec., 1939; 3:166–176.
15. Anliker, J., and Mayer, J.: An operant conditioning technique for studying feeding-fasting patterns in normal and obese mice. J. Appl. Physiol., 1956; 8:667–670.
16. Marshall, N. B.; Barnett, R. J., and Mayer, J.: Hypothalamic lesions in gold thioglucose injected mice. Proc. Soc. Exper. Biol. and Med., 1955; 90:240–244,.
17. Stunkard, A. J.; Grace, W. J., and Wolff, H. G.: The night-eating syndrome. A pattern of food intake among certain obese patients. Am. J. Med., 1955; 19:78–86,.
18. Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012; 10(1):22.
19. Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes 2005. 2008 Sep; 32(9):1431–7
20. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic. Obes Silver Spring Md. 2008; 16(10):2323–30.
21. Hu FB. Obesity epidemiology. Oxford University Press; Oxford; New York: 2008. p. 498.] [Hu FB. Obesity and Mortality: Watch Your Waist, Not Just Your Weight. Arch Intern Med. 2007; 167(9):875.
22. Ghosh R, Ganpathy P and Kadam V. Obesity- The gateway to metabolic syndrome.
23. http://www.dancewithshadows.com/pillscribe/sales-of-weight-loss-pill-sibutramine-could-be-prohibited-in-india/ Access on 04/02/2017
24. Powell A.G., Apovian C.M., Aronne L.J. New drug targets for the treatment of obesity. Clin. Pharmacol. Ther. 2011; 90:40–51. doi: 10.1038/clpt.2011.82
25. Barness L.A., Opitz J.M., Gilbert-Barness E. Obesity: Genetic, molecular, and environmental aspects. Am. J. Med. Genet. Part A. 2007; 143:3016–3034. doi: 10.1002/ajmg.a.32035
26. Ohta Y., Hatada Y., Nogi Y., Li Z., Ito S., Horikoshi K. Cloning, expression, and characterization of a glycoside hydrolase family 86 β-agarase from a deep-sea Microbulbifer-like isolate. Appl. Microbiol. Biotechnol. 2004; 66:266–275. doi: 10.1007/s00253-004-1757-5.
27. Buger GT, Miller CL. Animal care and facilities. In Principles and methods of toxicology.Wallace Hayes A, Raven Press Ltd New York: 1989; 2:527-31
28. Fernandez JA, Remesar X, Foz M, Alemany M. Pharmacological approaches for the treatment of obesity. Drugs, 2002; 62(6):915-44.
29. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gad-bois TM, et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000; 49:1390–4
30. Puavilai WMD, Laorugpongse DMD, Deerochanawong CMD, Muthapongthavorn RN, Srilert RN. The accuracy in using modified Friedewald equation to calculate LDL from non-fast triglyceride: a pilot study. J Med Assoc Thai 2009; 92 (2):182-7.
31. Young DS. Effect of drug on clinical laboratory test. ClinChem, Bosten 1972; 18(10)
Statistics
21 Views | 71 Downloads
How to Cite
Ahmad, M. F., Mani Babu, D. J., & Pradhan, A. (2018). EVALUATION OF ANTI DIABETIC DRUG ALOGLIPTIN FOR THE TREATMENT OF OBESITY IN RATS. Journal of Drug Delivery and Therapeutics, 8(5), 209-216. https://doi.org/10.22270/jddt.v8i5.1857